Skip to main content
. 2017 Nov 2;12(11):e0185813. doi: 10.1371/journal.pone.0185813

Fig 1. Serum HMGB1 levels during the PIVENS trial in the three treatment groups.

Fig 1

At baseline, serum HMGB1 levels among the three treatment groups were similar. Top panel: Serum HMGB1 levels did not change significantly during treatment either with placebo, vitamin E therapy (P = 0.81) or pioglitazone (P = 0.09). Middle panel: Serum HMGB1 levels did not differ among individuals with or without histological improvement irrespective of treatment assignment during study duration (P = 0.85). Bottom panel: Similarly, serum HMGB1 levels did not differ among individuals with or without resolution of NASH irrespective of treatment assignment during study duration (P = 0.29).